Monte Rosa Therapeutics (NASDAQ:GLUE) Stock Price Up 7.8% – Here’s Why

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) shares shot up 7.8% during trading on Tuesday . The stock traded as high as $19.57 and last traded at $20.1190. 341,754 shares changed hands during trading, a decline of 74% from the average daily volume of 1,304,115 shares. The stock had previously closed at $18.67.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on GLUE shares. JPMorgan Chase & Co. increased their price target on Monte Rosa Therapeutics from $30.00 to $31.00 and gave the company an “overweight” rating in a research note on Monday, May 11th. Weiss Ratings raised Monte Rosa Therapeutics from a “sell (d-)” rating to a “sell (d)” rating in a research note on Monday, May 11th. Wells Fargo & Company reduced their target price on Monte Rosa Therapeutics from $30.00 to $29.00 and set an “overweight” rating on the stock in a report on Wednesday, March 18th. Wall Street Zen downgraded shares of Monte Rosa Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, March 21st. Finally, Guggenheim lowered their price target on shares of Monte Rosa Therapeutics from $34.00 to $30.00 and set a “buy” rating for the company in a report on Wednesday, March 18th. Seven equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Monte Rosa Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $32.50.

Monte Rosa Therapeutics Stock Up 0.9%

The firm has a market cap of $1.76 billion, a P/E ratio of -14.11 and a beta of 1.60. The stock’s 50-day simple moving average is $18.79 and its 200 day simple moving average is $18.58.

Monte Rosa Therapeutics (NASDAQ:GLUE) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($0.45) earnings per share for the quarter, missing the consensus estimate of ($0.39) by ($0.06). The business had revenue of $4.21 million during the quarter, compared to the consensus estimate of $10.95 million. Monte Rosa Therapeutics had a negative return on equity of 40.99% and a negative net margin of 302.69%. On average, research analysts forecast that Monte Rosa Therapeutics, Inc. will post -1.23 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Monte Rosa Therapeutics news, insider Philip Nickson sold 5,845 shares of Monte Rosa Therapeutics stock in a transaction that occurred on Thursday, April 9th. The stock was sold at an average price of $17.69, for a total value of $103,398.05. Following the completion of the sale, the insider directly owned 55,000 shares in the company, valued at approximately $972,950. The trade was a 9.61% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Sharon Townson sold 3,000 shares of the business’s stock in a transaction that occurred on Wednesday, June 17th. The shares were sold at an average price of $19.00, for a total value of $57,000.00. Following the completion of the transaction, the insider directly owned 67,845 shares in the company, valued at approximately $1,289,055. This trade represents a 4.23% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 13,196 shares of company stock valued at $245,242 over the last 90 days. Company insiders own 6.40% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of GLUE. AQR Capital Management LLC acquired a new stake in Monte Rosa Therapeutics in the first quarter worth $1,065,000. Goldman Sachs Group Inc. increased its stake in Monte Rosa Therapeutics by 122.7% in the first quarter. Goldman Sachs Group Inc. now owns 356,112 shares of the company’s stock valued at $1,652,000 after purchasing an additional 196,238 shares in the last quarter. Acadian Asset Management LLC acquired a new position in shares of Monte Rosa Therapeutics during the first quarter valued at about $76,000. Geode Capital Management LLC raised its holdings in shares of Monte Rosa Therapeutics by 12.0% during the second quarter. Geode Capital Management LLC now owns 1,124,160 shares of the company’s stock valued at $5,071,000 after purchasing an additional 120,098 shares during the period. Finally, American Century Companies Inc. boosted its position in shares of Monte Rosa Therapeutics by 301.4% during the 2nd quarter. American Century Companies Inc. now owns 403,045 shares of the company’s stock worth $1,818,000 after purchasing an additional 302,639 shares in the last quarter. Institutional investors and hedge funds own 79.96% of the company’s stock.

Monte Rosa Therapeutics Company Profile

Monte Rosa Therapeutics is a biotechnology company focused on accelerating drug discovery through the integration of single-cell genomics and artificial intelligence. Founded in 2020 and headquartered in Cambridge, Massachusetts, the company has built a proprietary platform designed to identify novel therapeutic targets and optimize lead candidates for areas of high unmet medical need. By combining cutting-edge computational methods with comprehensive cellular profiling, Monte Rosa aims to streamline the preclinical development process and uncover insights into disease biology that might otherwise remain hidden.

The company’s main business activities center on using its AI-driven discovery engine to pursue programs in immuno-oncology and neuroscience.